Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Over 200 posters and other presentations of new data, as well as many other discussions and lectures, were offered yesterday in the prostate cancer sessions at the Genitourinary Cancers Symposium in Orlando.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: adjuvant, ADT, bicalutamide, CyberKnife, dutasteride, intermittent, pomegranate, SBRT, screening | 1 Comment »
RTOG 96-01 is a randomized, multi-center Phase III trial designed to compare bicalutamide monotherapy + salvage radiation therapy to a placebo + salvage radiation alone in men with pT2-3N0Mo prostate cancer who have an elevated PSA after surgery.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, outcome, radiation, RTOG 96-01, salvage | 2 Comments »
An article by a group of Romanian researchers published in October this year may have some controversial implications — so we want to be very clear that we don’t think too much should be read into it unless their data can be replicated by others.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, bicalutamide, effect, orientation, sexual | Leave a Comment »
Historically there have been few really compelling data available to support the use of an additional or alternative antiandrogen as a second-line agent to extend either progression-free or overall survival of castration-resistant prostate cancer (CRPC) patients who progress after first-line hormone therapy (whether they have been treated by orchiectomy or medical castration with an LHRH [...]
Filed under: Management, Treatment | Tagged: antiandrogen, bicalutamide, high-dose, hormone, second-line, therapy | Leave a Comment »
A number of physicians and patients have believed for years that so-called “triple” androgen blockade (ADT3) is a more effective option than an LHRH alone or combined androgen deprivation in the treatment of men with advanced prostate cancer. However, the clinical evidence supporting this belief has been limited.
Filed under: Management, Treatment | Tagged: ADT3, bicalutamide, dutasteride, TARP | 4 Comments »
In Europe, bicalutamide monotherapy with a dose of 150 mg/d is a widely used option for prostate cancer patients who wish to avoid the consequences of standard androgen deprivation using an LHRH agonist such as leuprolide acetate. However, bicalutamide induces gynecomastia (enlargement of the breasts) and mastalgia/mastodynia (pain in the breasts) in most patients.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, monotherapy, pprophylaxis, tamoxifen | 1 Comment »
According to a report from the Associated Press, generic bicalutamide (the generic form of Casodex) is now available in the USA after approval by the US Food and Drug Administration. This offers a significant potential cost saving for many prostate cancer patients that they may want to take advantage of.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, Casodex, generic | Comments Off
In today’s news reports we address such issues as: The possibility that type of initial treatment and comorbidities explain at least some racial disparities in prostate cancer survival Failure of time to surgery to explain racial disparities in post-treatment outcome Once-weekly bicalutamide as a regimen to prevent prostate cancer
Filed under: Management, Prevention, Treatment, Uncategorized | Tagged: bicalutamide, mortality, outcome, racial disparities, weekly | Leave a Comment »
The reports addressed today offer information from three very technical studies dealing with: Genomic profiling of localized prostate cancers among African American men “DNA licensing” and prostate cancer progression Interleukin-6 over-expression and bicalutamide resistance
Filed under: Diagnosis, Drugs in development, Prevention, Risk | Tagged: African American, bicalutamide, DNA licensing, genomic profile, interleukin-6 | Leave a Comment »
Newly published studies today include data on: Risk for patients with prostate atypia on biopsy having a subsequent diagnosis of prostate cancer Patterns of failure of patients treated with brachytherapy for localized disease Quality of life following differing types of radiotherapy Second-line antiandrogen therapy following initial failure of a first-line antiandrogen in advanced prostate cancer [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, antiandrogen, atypia, bicalutamide, brachytherapy, cancer, depression, fatigue, flutamide, irritability, mood, prostate, quality of life, radiotherapy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site